Cargando…

The Nobel Prize of Physiology or Medicine, 1923: controversies on the discovery of the antidiabetic hormone

AIMS: To analyze the main contributions to the discovery of the antidiabetic hormone in the period between 1889, the year in which Oskar Minkowski demonstrated that complete pancreatectomy in dogs caused diabetes, and the year 1923, the date in which the clinical use of insulin was consolidated. A m...

Descripción completa

Detalles Bibliográficos
Autores principales: de Leiva-Hidalgo, Alberto, de Leiva-Pérez, Alejandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359383/
https://www.ncbi.nlm.nih.gov/pubmed/37266749
http://dx.doi.org/10.1007/s00592-023-02098-9
_version_ 1785075869696393216
author de Leiva-Hidalgo, Alberto
de Leiva-Pérez, Alejandra
author_facet de Leiva-Hidalgo, Alberto
de Leiva-Pérez, Alejandra
author_sort de Leiva-Hidalgo, Alberto
collection PubMed
description AIMS: To analyze the main contributions to the discovery of the antidiabetic hormone in the period between 1889, the year in which Oskar Minkowski demonstrated that complete pancreatectomy in dogs caused diabetes, and the year 1923, the date in which the clinical use of insulin was consolidated. A main objective has been to review the controversies that followed the Nobel Prize and to outline the role of the priority rule in Science. METHODS: We have considered the priority rule defined by Robert Merton in 1957, which takes into account the date of acceptance of the report of a discovery in an accredited scientific journal and/or the granting of a patent, complemented by the criteria set out by Ronald Vale and Anthony Hyman (2016) regarding the transfer of information to the scientific community and its validation by it. The awarding of the Nobel Prize in Physiology or Medicine in October 1923 has represented a frame of reference. The claims and disputes regarding the prioritization of the contributions of the main researchers in the organotherapy of diabetes have been analyzed through the study of their scientific production and the debate generated in academic institutions. MAIN RESULTS AND CONCLUSIONS: (1) According to the criteria of Merton, Vale and Hyman, the priority of the discovery of the antidiabetic hormone corresponds to the investigations developed in Europe by E. Gley (1900), GL Zülzer (1908) and NC Paulescu (1920). (2) The active principle of the pancreatic extracts developed by Zülzer (acomatol), Paulescu (pancreina) and Banting and Best (insulin) was the same. (3) JB Collip succeeded in isolating the active ingredient from the pancreatic extract in January 1922, eliminating impurities to the point of enabling its use in the clinic. (4) In 1972, the Nobel Foundation modified the purpose of the 1923 Physiology or Medicine award to Banting and Macleod by introducing a new wording: "the credit for having produced the pancreatic hormone in a practical available form" (instead of “for the discovery of insulin”). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00592-023-02098-9.
format Online
Article
Text
id pubmed-10359383
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-103593832023-07-22 The Nobel Prize of Physiology or Medicine, 1923: controversies on the discovery of the antidiabetic hormone de Leiva-Hidalgo, Alberto de Leiva-Pérez, Alejandra Acta Diabetol Original Article AIMS: To analyze the main contributions to the discovery of the antidiabetic hormone in the period between 1889, the year in which Oskar Minkowski demonstrated that complete pancreatectomy in dogs caused diabetes, and the year 1923, the date in which the clinical use of insulin was consolidated. A main objective has been to review the controversies that followed the Nobel Prize and to outline the role of the priority rule in Science. METHODS: We have considered the priority rule defined by Robert Merton in 1957, which takes into account the date of acceptance of the report of a discovery in an accredited scientific journal and/or the granting of a patent, complemented by the criteria set out by Ronald Vale and Anthony Hyman (2016) regarding the transfer of information to the scientific community and its validation by it. The awarding of the Nobel Prize in Physiology or Medicine in October 1923 has represented a frame of reference. The claims and disputes regarding the prioritization of the contributions of the main researchers in the organotherapy of diabetes have been analyzed through the study of their scientific production and the debate generated in academic institutions. MAIN RESULTS AND CONCLUSIONS: (1) According to the criteria of Merton, Vale and Hyman, the priority of the discovery of the antidiabetic hormone corresponds to the investigations developed in Europe by E. Gley (1900), GL Zülzer (1908) and NC Paulescu (1920). (2) The active principle of the pancreatic extracts developed by Zülzer (acomatol), Paulescu (pancreina) and Banting and Best (insulin) was the same. (3) JB Collip succeeded in isolating the active ingredient from the pancreatic extract in January 1922, eliminating impurities to the point of enabling its use in the clinic. (4) In 1972, the Nobel Foundation modified the purpose of the 1923 Physiology or Medicine award to Banting and Macleod by introducing a new wording: "the credit for having produced the pancreatic hormone in a practical available form" (instead of “for the discovery of insulin”). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00592-023-02098-9. Springer Milan 2023-06-02 2023 /pmc/articles/PMC10359383/ /pubmed/37266749 http://dx.doi.org/10.1007/s00592-023-02098-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
de Leiva-Hidalgo, Alberto
de Leiva-Pérez, Alejandra
The Nobel Prize of Physiology or Medicine, 1923: controversies on the discovery of the antidiabetic hormone
title The Nobel Prize of Physiology or Medicine, 1923: controversies on the discovery of the antidiabetic hormone
title_full The Nobel Prize of Physiology or Medicine, 1923: controversies on the discovery of the antidiabetic hormone
title_fullStr The Nobel Prize of Physiology or Medicine, 1923: controversies on the discovery of the antidiabetic hormone
title_full_unstemmed The Nobel Prize of Physiology or Medicine, 1923: controversies on the discovery of the antidiabetic hormone
title_short The Nobel Prize of Physiology or Medicine, 1923: controversies on the discovery of the antidiabetic hormone
title_sort nobel prize of physiology or medicine, 1923: controversies on the discovery of the antidiabetic hormone
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359383/
https://www.ncbi.nlm.nih.gov/pubmed/37266749
http://dx.doi.org/10.1007/s00592-023-02098-9
work_keys_str_mv AT deleivahidalgoalberto thenobelprizeofphysiologyormedicine1923controversiesonthediscoveryoftheantidiabetichormone
AT deleivaperezalejandra thenobelprizeofphysiologyormedicine1923controversiesonthediscoveryoftheantidiabetichormone
AT deleivahidalgoalberto nobelprizeofphysiologyormedicine1923controversiesonthediscoveryoftheantidiabetichormone
AT deleivaperezalejandra nobelprizeofphysiologyormedicine1923controversiesonthediscoveryoftheantidiabetichormone